The goal of this interventional study is to evaluate the effectiveness of DHA (docosahexaenoic acid) & ARA (arachidonic acid) Candy on the cognitive development of preschool children (2-6 years old). The main questions it aims to answer are:

- Does DHA & ARA Candy improve the cognitive ability in terms of Wechsler Intelligence Scale for Children 4th edition-Chinese version (WISC-IV-Chinese)?

Researchers will administer the WISC-IV-Chinese following the guidelines strictly and analyze the score to conclude whether the DHA & ARA is effective to improve the cognitive ability of preschool childchildren.

Participants will eat 1-2 candy (each contains 100mg DHA and 100mg ARA) daily for 4 consecutive weeks and take the WISC-IV-Chinese test for three times according to the protocol.

Inclusion Criteria:

• Participants must be 2-6 years old
• Healthy children of normal development, without gender restrictions, with a male to female ratio of more than 40%;
• During the trial period, participants agree not to take any medications, supplements, or other nutritional products containing DHA and ARA;
• Parents or legal guardians (at least one party) have signed an informed consent form, voluntarily participating in this study and complying with the study design;
• Willing to not participate in other interventional nutritional studies during the trial period;
• Capable of fully understanding the nature, purpose, benefits, and potential risks and side effects of this study.

Exclusion Criteria:

• Allergic to dairy products;
• Severely intolerant to milk dairy products;
• Unable to provide written informed consent;
• During the screening period, or within the past two weeks, has used antibiotics;
• Currently taking therapeutic medications;
• The volunteer has any of the following medical histories or has been nutritionally diagnosed with any of the following diseases: significant gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory, or cardiovascular diseases, which may affect the assessment of the trial's effects;
• Suffering from any gastrointestinal dysfunction or gastrointestinal disease. For example, but not limited to: Irritable Bowel Syndrome (IBS), enteritis, ulcerative colitis, celiac disease, irritable bowel syndrome;
• Has a history of hospitalization within the past 3 months;
• According to the researcher's judgment, currently frequently using medications that may affect gastrointestinal function or the immune system.

The abstract of the study result will be shared via a public web link

The abstract will be available in early November, 2024, and there is no end date for the sharing unless further notice.

The study result is available to access for the public via the following link http://www.raisonbiotech.com/Data/24-RD-06-SBT-001-Abstract.pdf